Pharmacology Core

药理学核心

• 批准号: 8326902
• 负责人: Angela D Kashuba
• 金额: $ 22.61万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-08 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8326902
• 关键词: Algorithms; Analytical Chemistry; Animal Model; Animals; Anti-Retroviral Agents; Biological; Biological Assay; Biological Models; Cell Culture Techniques; Cells; Clinical; Clinical Pharmacology; Clinical Trials; Clinical Trials Design; Data; Development; Dose; Drug Exposure; Drug Kinetics; Frequencies; HIV; HIV Infections; HIV-1; Human; Industry; Infection; Lead; Leadership; Logistics; Marketing; Modeling; Monkeys; Mus; North Carolina; Outcome; Pharmaceutical Preparations; Pharmacology; Plasma; Plasma Cells; Production; Research Contracts; Research Design; Research Personnel; Resources; Role; Sampling; Screening procedure; Techniques; Testing; Therapeutic; Therapeutic Studies; Tissues; Toxic effect; Toxicology; Universities; Validation; Viral; base; collaboratory; design; drug development; experience; indexing; mouse model; nonhuman primate; pharmacodynamic model; pre-clinical; preclinical study; scale up; simulation; small molecule; small molecule libraries; success

The role of Preclinical and Clinical Pharmacology is to maximize the likelihood of success of an identified candidate, or to quickly remove a likely unsuccessful candidate from progressing into further testing. The primary objective of the Pharmacology Core (Core B) is to provide the investigators of the Martin Deianey Collaboratory to Eradicate HlV-1 Infection with the pharmacologic expertise to study therapeutic strategies that reduce the latent viral pool and animal model systems, and to evaluate the pharmacologic basis of viral persistence in humans. The Pharmacology Core will coordinate access to chemical libraries, assist with lead candidate production scale-up, coordinate animal toxicology studies, analyze biological matrices for drug concentrations (both antiretroviral and induction/eradication compounds), provide pharmacokinetic/ pharmacodynamic (PK/PD) modeling for optimal dose and dose frequency selection, and perform trial simulation to optimize design and sampling strategies. This Core will participate in all aspects of drug development for identifying and progressing lead induction/eradication candidates. The Core leadership team (Drs. Kashuba and Tan) has over 20 years combined experience in preclinical and clinical pharmacology, analytical chemistry, and Core management, and are well-suited to support the projects in the Collaboratory. This results in a Core which combines academic and industry resources to synergize strengths.

临床前和临床药理学的作用是最大限度地提高鉴定成功的可能性